Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

/p>

On August 28, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the publication of complete study results from Phase I trials with ALN-TTR0a and ALN-TTR02 in a article titled "Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis" in the New England Journal of Medicine. Alnylam informed that the article shows that RNAi therapeutics targeting transthyretin (TTR) achieved rapid, dose-dependent, durable, and specific knockdown of the TTR, the disease causing protein in the TTR mediated amyloidosis (ATTR). Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said, "The Phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general, and we are thrilled to be publishing these landmark data in the New England Journal of Medicine. Notably, this is the first time that clinical results with an RNAi therapeutic have been published in the Journal, and we are proud to be associated with this milestone as we lead the clinical translation of RNAi therapeutics as a whole new class of innovative medicines." The Full Research Report on Alnylam Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for
    '/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
(Date:7/29/2014)... , July 29, 2014   Health 2.0 ... a keynote alongside visionary physicians Eric Topol , ... at the Health 2.0 8th Annual Fall Conference ... This year, Health 2.0 is set to host ... of the larger session on Consumer Tech & Wearables: ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... webcast to discuss financial results for the second quarter of ... 2014 at 4:30 p.m. ET. Conference call ... 2014 Time: 4:30 PM ET Listen via Internet: http://ir.pharmacyclics.com/events.cfm ... A webcast replay will be available on the Pharmacyclics website ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Inc. (OTC Bulletin Board: WGBS ), a leading developer ... an overview of the company at the 13th annual BIO CEO ... Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern time.  The ... may be accessed at www.wafergen.com . The BIO ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) ... protocols on its Sciclone® NGS Workstation for Illumina,s TruSeq™ ... In addition to the automation protocols for TruSeq kits, ... library preparation kits, as well as for Agilent,s SureSelect™ ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols 2
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical Trials ... only provided a comprehensive and thorough knowledge of the ... registration but also introduced the practical operation how to ... use the Chinese trial venues to keep drug development ... step. , The audiences of this guidebook are overseas ...
(Date:7/29/2014)... controversy over how best to treat patients after they,ve ... until the cancer comes back or provide men with ... a new study from Thomas Jefferson University ... patients make a more informed decision. , "We are ... author Robert Den, M.D., Assistant Professor of Radiation Oncology ...
(Date:7/29/2014)... principle suitable to find out which preferences patients have ... health economic evaluations, some (primarily methodological) issues still need ... pilot project by the German Institute for Quality and ... Process (AHP), CA is the second method tested by ... outcome-specific results to an overall value , In ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... stressful situations better than others, and it,s not ... differences in how they respond. , Researchers have ... of genetically identical mice that predicts how well ... , The findings, published July 29 in ... potential consequences of chronic stress -- such as ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2
... 26 Concentric Medical, Inc., the global leader in ... announced that the company,s Merci Retrieval System(TM) has been ... August 2004. The Merci Retrieval System is a ... remove blood clots from patients suffering an ischemic stroke. ...
... Group at Frost & Sullivan is ... Presentation on the European Orphan Diseases Market to ... 2 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Today,s pharmaceutical companies ... market because of the patent expiry of blockbuster ...
... of advanced health screening solutions in local communities, announces the deployment ... make the investment in the new unit in response to increased ... to increased capacity requirements related to the company,s planned geographical expansion ... ...
... Inc. anticipates growth and expansion of telemedicine services to include ... mental health centers. , ... N. ... continues to advance, regulations pertaining to hospital and physician reimbursement ...
... tumor characteristics that may help indicate which breast cancer patients ... to remove the unaffected breast. Published in the March ... of the American Cancer Society, the study could help patients ... diagnosed with breast cancer are known to be at increased ...
... procedure to remove the unaffected breast in breast cancer patients ... patients who have high-risk features as assessed by examining the ... to researchers at The University of Texas M. D. Anderson ... 1, 2009 issue of Cancer , may help physicians ...
Cached Medicine News:Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future? 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 2Health News:HealthYes! Announces Deployment of a New Mobile Health Screening Unit 3Health News:A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009 2Health News:Study examines risk factors for cancer in unaffected breast of breast cancer patients 2Health News:Researchers identify risk factors for contralateral breast cancer 2
... eyewear and sunwear, inspired by ... personal style, with long lasting ... the collection include sophistication, elegance ... offer clean modern shapes, classic ...
... designs with children in mind, making eyewear ... stay-put cable temples. Its not surprising that ... as the best selling childrens collection from ... popular is its ability to keep pace ...
... The Calvin Klein Collection. Provocatively inspired ... - a bold outlook. Innovative structure: ... Modern technology enhances modern design. Technological ... and enhance the face., ,The Calvin ...
Inquire...
Medicine Products: